Roila F, Bracarda S, Basurto C, Sassi M, Lupattelli M, Picciafuoco M, Boschetti E, Del Favero A, Tonato M
Medical Oncology Division, Policlinico Hospital, Perugia, Italy.
Am J Clin Oncol. 1992 Apr;15(2):112-4. doi: 10.1097/00000421-199204000-00003.
The antiemetic activity of two different high doses and schedules of metoclopramide in dacarbazine-treated cancer patients was compared in a double-blind crossover study. Regimen A consisted of metoclopramide [2 mg/kg x 4 intravenously (i.v.)] plus methylprednisolone (250 mg x 2 i.v.) plus diphenhydramine (50 mg x 2 i.v.). Regimen B consisted of metoclopramide (3 mg/kg x 2 i.v.) plus dexamethasone (20 mg i.v.) and diphenhydramine (50 mg i.v.). Both treatments were administered for the first 2 days of 5-day dacarbazine chemotherapy. Thirty-two patients (13 men and 19 women) affected by melanoma and sarcoma were entered in the study. Complete protection against nausea and vomiting for the first 2 days of chemotherapy in both antiemetic regimens was not significantly different. Patient preference and tolerance of the two antiemetic treatments were similar. Regimen B, employing a lower dosage of metoclopramide and steroids and using a more simple schedule of administration should be the preferred treatment.
在一项双盲交叉研究中，比较了两种不同高剂量及给药方案的甲氧氯普胺对接受达卡巴嗪治疗的癌症患者的止吐活性。方案A包括甲氧氯普胺[2毫克/千克静脉注射4次]加甲泼尼龙（250毫克静脉注射2次）加苯海拉明（50毫克静脉注射2次）。方案B包括甲氧氯普胺（3毫克/千克静脉注射2次）加地塞米松（20毫克静脉注射）和苯海拉明（50毫克静脉注射）。两种治疗均在为期5天的达卡巴嗪化疗的头2天给药。32例（13例男性和19例女性）患有黑色素瘤和肉瘤的患者进入该研究。两种止吐方案在化疗头2天对恶心和呕吐的完全防护作用无显著差异。患者对两种止吐治疗的偏好和耐受性相似。采用较低剂量甲氧氯普胺和类固醇且给药方案更简单的方案B应是首选治疗方法。
